CRESCENT BIOPHARMA, INC.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

CBIO$13.65+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Crescent Biopharma, Inc.
Date: February 26, 2026	By:	/s/ Joshua Brumm
	Joshua Brumm
	Chief Executive Officer
	(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Joshua Brumm
Signature	Title	Date
/s/ Joshua Brumm	Director and Chief Executive Officer (principal executive officer)	February 26, 2026
/s/ Richard Scalzo	Chief Financial Officer(principal financial officer)	February 26, 2026
Richard Scalzo
/s/ Ryan Lynch	Treasurer, Senior Vice President of Finance and Chief Accounting Officer(principal accounting officer)	February 26, 2026
Ryan Lynch
/s/ Peter Harwin	Chair and Director	February 26, 2026
Peter Harwin
/s/ Alexandra Balcom	Director	February 26, 2026
Alexandra Balcom
/s/ David Lubner	Director	February 26, 2026
David Lubner
/s/ Susan Moran	Director	February 26, 2026
Susan Moran, M.D.
/s/ Jonathan Violin	Director	February 26, 2026
Jonathan Violin, Ph.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.